The everyday clinical management of inner ear pathologies, by the point of view of the therapeutic approach, induced us to select one kind of drug as preferred for the treatment of sudden and chronic hearing loss: recombinant glycoprotein analogous tissutal plasminogen activator (rt-PA). Eighty patients with sudden hearing loss (SHL) and eighty patients with a chronical decreased cochlear function (CHL) have been treated until now with intravenous infusion of rt-PA. No patient had side effects from the treatment and the functional results are excellent at all, much more if compared with the protocols of therapy previously used for this kind of disease.
Treatment of sensory hearing loss by rt-PA: Three years' experience
Mora R.;Mora F.;Ottoboni S.;Barbieri M.
2003-01-01
Abstract
The everyday clinical management of inner ear pathologies, by the point of view of the therapeutic approach, induced us to select one kind of drug as preferred for the treatment of sudden and chronic hearing loss: recombinant glycoprotein analogous tissutal plasminogen activator (rt-PA). Eighty patients with sudden hearing loss (SHL) and eighty patients with a chronical decreased cochlear function (CHL) have been treated until now with intravenous infusion of rt-PA. No patient had side effects from the treatment and the functional results are excellent at all, much more if compared with the protocols of therapy previously used for this kind of disease.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
